Pliant Therapeutics Shares Receive $3.00 Average Price Target

Analysts issue mixed ratings on the biotech company's stock performance.

Apr. 20, 2026 at 7:11am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, industrial banking machinery and mechanisms, rendered in high contrast black and white, conveying a sense of the physical power and security of financial institutions.A dramatic close-up of the inner workings of the financial system highlights the complex machinery that underpins the markets and banking institutions.Redwood City Today

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) have received an average price target of $3.00 from the five analysts currently covering the company, according to Marketbeat.com. The analysts' recommendations range from 'Reduce' to 'Buy', with two sell ratings, two hold ratings, and one buy rating.

Why it matters

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for fibrotic diseases. The mixed analyst ratings and relatively low average price target suggest uncertainty around the company's near-term prospects, which could impact investor sentiment and the stock's performance.

The details

The analysts' price targets for Pliant Therapeutics range from $3.00 to $4.00, with the average target being $3.00. Weiss Ratings reissued a 'sell (e+)' rating on the stock, while Piper Sandler and Canaccord Genuity Group both lowered their price targets to $3.00, from $4.00 previously.

  • Pliant Therapeutics reported its latest financial results on March 11, 2026.
  • The analysts' price targets and recommendations were issued within the last year.

The players

Pliant Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing treatments for fibrotic diseases. The company's lead product candidate is PLN-74809, an oral small molecule designed to inhibit integrins involved in fibrosis.

Weiss Ratings

A research firm that provides investment research and ratings, including a 'sell (e+)' rating on Pliant Therapeutics' stock.

Piper Sandler

An investment bank that covers Pliant Therapeutics and lowered its price target on the stock from $4.00 to $3.00.

Canaccord Genuity Group

An investment bank that also lowered its price target on Pliant Therapeutics from $4.00 to $3.00.

Got photos? Submit your photos here. ›

The takeaway

The mixed analyst sentiment and relatively low average price target for Pliant Therapeutics' stock suggest that the market is uncertain about the company's near-term prospects, despite its focus on developing treatments for fibrotic diseases, which is an area of significant unmet medical need.